About NouscomNouscom is a private oncology company developing next generation immunotherapies. Nouscom's proprietary technology platform harnesses the full power of immune response by combining oncolytic viruses specifically targeted to a tumor with viral vectored genetic vaccines based on patient specific neo-antigens.
Co-Founder and CEO of HQ: Riccardo Cortese, PhD, MD
Co-Founder and CEO of Italy: Alfredo Nicosia, PhD
Co-Founder and CSO: Elisa Scarselli, MD
Co-Founder and CTO: Stefano Colloca, MD
Co-Founder and Head of Immunology: Antonella Folgori, PhD
Co-Founder and Senior Director of Regulatory Affairs: Cinzia Traboni, PhD
COO: Marina Udier, PhD
Please click here for Nouscom's science.
16 articles with Nouscom
Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy
Nouscom announced that new translational data obtained from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma has been accepted for presentation in a Late-Breaking session at the 2023 American Association for Cancer Research Annual Meeting.
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
Clinical Catch-Up: November 8-12
11/15/2021It was another busy week for clinical trial news. Here’s a look.
Clinical Catch-Up: September 13-17
9/20/2021With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
Clinical Catch-Up: March 8-12
3/15/2021It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.
BioSpace Movers & Shakers, Feb. 28
2/28/2020Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers.
BioSpace Global Roundup, Dec. 12
12/12/2019Companies from across the globe provide updates to their business and pipelines.
BioSpace Global Roundup, June 6
6/6/2019Companies from across the globe share updates on their pipelines and growth strategies.
Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director
Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model
Nouscom, an oncology company developing next generation cancer vaccines based on its Exovax platform, today announced preclinical data of its neoantigen-based cancer vaccine in combination with Nektar Therapeutics' NKTR-214, a CD122-biased cytokine agonist which is currently in clinical trials.
The round was led by new investor Abingworth with participation from another new investor, 5AM Ventures, LSP and Versant Ventures.
Nouscom Appoints New Chief Operating Officer And Strengthens The Board Of Directors